Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting
Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…Abstract Number: 2923 • 2014 ACR/ARHP Annual Meeting
Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis
Background/Purpose: Targeted biologic therapies with different mechanisms of action are commonly used in RA. Abatacept is a recombinant fusion protein that inhibits T-cell co-stimulatory molecules…Abstract Number: 1407 • 2014 ACR/ARHP Annual Meeting
Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF-Alpha Treatment
Background/Purpose The induction of remission is the primary target of RA therapy. Failing to achieve the patient global estimate of disease activity criterion (PGAAbstract Number: 2912 • 2014 ACR/ARHP Annual Meeting
Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program
Background/Purpose . There is limited data on adherence to treat-to-target (T2T) strategies in RA in real world-practice and the impact of failure to adopt this…Abstract Number: 1384 • 2014 ACR/ARHP Annual Meeting
Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients
Background/Purpose: Fibromyalgia (FM) occurs commonly in patients with rheumatoid arthritis (RA) and its effect on treatment response is unknown. In this study we aimed to…Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…Abstract Number: 1797 • 2013 ACR/ARHP Annual Meeting
A Randomized, Dose-Ranging, Placebo-Controlled, 84-Day Study Of INCB039110, a Selective Janus Kinase-1 Inhibitor, In Patients With Active Rheumatoid Arthritis
Background/Purpose: To characterize the safety and efficacy of INCB039110, a novel and selective JAK1 inhibitor, in patients with active RA. Methods: This phase 2, multicenter…Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…Abstract Number: 1482 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Treatment In Chronic Inflammatory Arthritis: A Preliminary Analysis Of 13 Years Of Follow Up In Clinical Practice
Background/Purpose: The wide use of biological therapies (BTs) has largely modified the therapeutic approach in Chronic Inflammatory Arthritis (CIA). These relatively new drugs have different…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- Next Page »